» Articles » PMID: 33578800

Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Feb 13
PMID 33578800
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a rising chronic liver disease and comprises a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) to end-stage cirrhosis and risk of hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is multifactorial, but inflammation is considered the key element of disease progression. The liver harbors an abundance of resident immune cells, that in concert with recruited immune cells, orchestrate steatohepatitis. While inflammatory processes drive fibrosis and disease progression in NASH, fueling the ground for HCC development, immunity also exerts antitumor activities. Furthermore, immunotherapy is a promising new treatment of HCC, warranting a more detailed understanding of inflammatory mechanisms underlying the progression of NASH and transition to HCC. Novel methodologies such as single-cell sequencing, genetic fate mapping, and intravital microscopy have unraveled complex mechanisms behind immune-mediated liver injury. In this review, we highlight some of the emerging paradigms, including macrophage heterogeneity, contributions of nonclassical immune cells, the role of the adaptive immune system, interorgan crosstalk with adipose tissue and gut microbiota. Furthermore, we summarize recent advances in preclinical and clinical studies aimed at modulating the inflammatory cascade and discuss how these novel therapeutic avenues may help in preventing or combating NAFLD-associated HCC.

Citing Articles

Effect of time-restricted feeding and caloric restriction in metabolic associated fatty liver disease in male rats.

Deng J, Ma J, Zhang X, Wang K, Wang Y, Gao N Nutr Metab (Lond). 2025; 22(1):14.

PMID: 39972306 PMC: 11841360. DOI: 10.1186/s12986-025-00906-3.


Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma.

Alpizar Salazar M, Olguin Reyes S, Medina Estevez A, Saturno Lobos J, De Aldecoa Castillo J, Carrera Aguas J Medicina (Kaunas). 2025; 61(1).

PMID: 39859069 PMC: 11766802. DOI: 10.3390/medicina61010088.


Diagnostic Value of Hepatic Mast Cell Concentration (MCC) in NAFLD and NASH Severity and Fibrosis Grade.

Panahi M, Rakhshani N, Sarhaddi A, Afzalaghaee M, Rezvani H, Emtiazi N Iran J Pathol. 2024; 19(3):291-299.

PMID: 39687460 PMC: 11646207. DOI: 10.30699/IJP.2024.2016320.3216.


A Comprehensive Analysis of Liver Lipidomics Signature in Adults with Metabolic Dysfunction-Associated Steatohepatitis-A Pilot Study.

Mouskeftara T, Kalopitas G, Liapikos T, Arvanitakis K, Theocharidou E, Germanidis G Int J Mol Sci. 2024; 25(23).

PMID: 39684777 PMC: 11642547. DOI: 10.3390/ijms252313067.


Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model.

Liu H, Yin G, Kohlhepp M, Schumacher F, Hundertmark J, Hassan M Adv Sci (Weinh). 2024; 11(30):e2403516.

PMID: 38868948 PMC: 11321671. DOI: 10.1002/advs.202403516.


References
1.
Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

2.
Heinrich B, Brown Z, Diggs L, Vormehr M, Ma C, Subramanyam V . Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology. 2020; 160(1):331-345.e6. PMC: 7755834. DOI: 10.1053/j.gastro.2020.09.031. View

3.
Ou R, Liu J, Lv M, Wang J, Wang J, Zhu L . Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice. Endocrine. 2017; 57(1):72-82. DOI: 10.1007/s12020-017-1323-4. View

4.
Chen J, Liang B, Bian D, Luo Y, Yang J, Li Z . Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism. Biochem Biophys Res Commun. 2019; 518(4):691-697. DOI: 10.1016/j.bbrc.2019.08.111. View

5.
Kessoku T, Imajo K, Honda Y, Kato T, Ogawa Y, Tomeno W . Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. Sci Rep. 2016; 6:22251. PMC: 4766502. DOI: 10.1038/srep22251. View